Related Experiment Video
Updated: Feb 22, 2026

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
LSD1-Mediated Epigenetic Reprogramming Drives CENPE Expression and Prostate Cancer Progression
Yi Liang1, Musaddeque Ahmed1, Haiyang Guo1
1Princess Margaret Cancer Centre/University Health Network, Toronto, Ontario, Canada.
Abstract:
Androgen receptor (AR) signaling is a key driver of prostate cancer, and androgen-deprivation therapy (ADT) is a standard treatment for patients with advanced and metastatic disease. However, patients receiving ADT eventually develop incurable castration-resistant prostate cancer (CRPC). Here, we report that the chromatin modifier LSD1, an important regulator of AR transcriptional activity, undergoes epigenetic reprogramming in CRPC. LSD1 reprogramming in this setting activated a subset of cell-cycle genes, including CENPE, a centromere binding protein and mitotic kinesin. CENPE was regulated by the co-binding of LSD1 and AR to its promoter, which was associated with loss of RB1 in CRPC. Notably, genetic deletion or pharmacological inhibition of CENPE significantly decreases tumor growth. Our findings show how LSD1-mediated epigenetic reprogramming drives CRPC, and they offer a mechanistic rationale for its therapeutic targeting in this disease. Cancer Res; 77(20); 5479-90. ©2017 AACR.
Insights
Chromatin modifier LSD1 reprogramming drives castration-resistant prostate cancer (CRPC) by activating cell-cycle genes like CENPE. Targeting CENPE significantly reduces tumor growth, offering a new therapeutic strategy for CRPC.
Area of Science:
- Oncology
- Epigenetics
- Molecular Biology
Background:
- Androgen receptor (AR) signaling drives prostate cancer.
- Androgen-deprivation therapy (ADT) is a standard treatment but leads to castration-resistant prostate cancer (CRPC).
- The chromatin modifier LSD1 regulates AR activity.
Purpose of the Study:
- Investigate epigenetic reprogramming of LSD1 in CRPC.
- Identify genes regulated by LSD1 in CRPC.
- Determine the therapeutic potential of targeting LSD1-regulated genes.
Main Methods:
- Analysis of LSD1 epigenetic reprogramming in CRPC models.
- Identification of LSD1 and AR co-binding targets.
- Genetic deletion and pharmacological inhibition of CENPE.
Main Results:
- LSD1 undergoes epigenetic reprogramming in CRPC.
- Reprogramming activates cell-cycle genes, including CENPE, via LSD1 and AR co-binding.
- Loss of RB1 is associated with CENPE regulation in CRPC.
- CENPE inhibition significantly decreases CRPC tumor growth.
Conclusions:
- LSD1-mediated epigenetic reprogramming drives CRPC progression.
- CENPE is a key driver of CRPC growth.
- Targeting CENPE offers a promising therapeutic strategy for CRPC.
Related Concept Videos
Epigenetic Regulation
X-chromosome...
Epigenetic Regulation
Abnormal Proliferation
Master Transcription Regulators
Methods of Nuclear Reprogramming
Induced Pluripotent Stem Cells
Somatic...

